Zaire ebolavirus

Discovery and history

Zaire ebolavirus was first isolated in 1976 during a near-simultaneous pair of outbreaks: one near the Ebola River in northern Zaire (now the Democratic Republic of the Congo), and another in southern Sudan that was initially assumed to be the same virus but turned out to be a distinct species (now Sudan ebolavirus). The Zaire outbreak in Yambuku, traced largely to a Catholic mission hospital that re-used unsterilized needles for antenatal injections, killed 280 of 318 reported cases — an 88 percent case-fatality rate that set the early reputation of Ebola as among the most lethal known viral infections. The virus was named for the river to avoid stigmatizing the village itself.

Reservoir (suspected)

The natural reservoir is strongly suspected but not definitively confirmed to be fruit bats of the family Pteropodidae — in particular Hypsignathus monstrosus (hammer-headed bat), Epomops franqueti (Franquet's epauletted fruit bat), and Myonycteris torquata (little collared fruit bat). Serological evidence of ebolavirus exposure in these species has been documented across the Congo Basin and West Africa. Spillover into humans is thought to occur both directly (contact with bat saliva, urine, or droppings, often via fruit bats roosting in trees or buildings) and indirectly (hunting and butchering primates or other forest mammals that have themselves been infected by bat material). Once a spillover occurs, the human-to-human transmission cycle takes over and the wildlife reservoir is no longer epidemiologically relevant for the duration of the outbreak.

Geographic distribution

Zaire ebolavirus circulates across the equatorial forest belt of Central Africa — Democratic Republic of the Congo, Gabon, Republic of Congo, with sporadic spillovers documented elsewhere. The 2014 to 2016 epidemic originated in southeastern Guinea and spread across Sierra Leone and Liberia, the first time the species had been documented in West Africa. The DRC has experienced more Zaire ebolavirus outbreaks than any other country, with 14 outbreaks recorded in Equateur, North Kivu, and other provinces between 1976 and 2024.

Clinical features

Ebola virus disease begins after an incubation period of two to twenty-one days (typically eight to ten) with sudden fever, severe headache, myalgia, fatigue, and pharyngitis. Within several days patients develop vomiting, watery diarrhea, abdominal pain, and a maculopapular rash. The volume of fluid loss is extreme — patients with severe disease can lose five to ten liters per day to diarrhea, driving profound electrolyte derangements and hypovolemic shock. Hemorrhagic manifestations (petechiae, conjunctival hemorrhage, bleeding from venipuncture sites, gastrointestinal bleeding) appear in roughly half of severe cases. Death, when it occurs, is typically between days seven and sixteen and is driven by hemorrhagic shock, multi-organ failure, or both. Case-fatality has ranged from 44 percent in the 2014-2016 West Africa epidemic to 88 percent in early outbreaks — the variability tracks closely with access to early supportive care, particularly aggressive intravenous fluid and electrolyte replacement.

Notable outbreaks

The 1976 Yambuku outbreak in Zaire (318 cases, 280 deaths) was the original Ebola event. The 1995 Kikwit outbreak in DRC (315 cases, 254 deaths) brought Ebola into wider international consciousness and triggered the first systematic infection-control response by an international team. The 2000 Gulu outbreak in northern Uganda spread to healthcare workers and produced 425 cases — although that outbreak was Sudan ebolavirus rather than Zaire. The defining Zaire ebolavirus event is the 2014 to 2016 West Africa epidemic: 28,616 reported cases, 11,310 deaths across Guinea, Sierra Leone, and Liberia, and the first ebolavirus exportation to the United States and Europe. The 2018 to 2020 North Kivu outbreak in DRC was the second-largest Ebola event ever (3,481 cases, 2,299 deaths) and saw the first widespread deployment of the rVSV-ZEBOV vaccine under a ring-vaccination strategy.

Prevention

The licensed vaccine Ervebo (rVSV-ZEBOV) protects against Zaire ebolavirus and is the cornerstone of outbreak response. WHO's ring-vaccination strategy — immunizing contacts of confirmed cases and contacts of contacts within days of identification — has interrupted transmission chains in DRC outbreaks since 2018. Beyond vaccination, infection prevention and control in healthcare facilities (PPE, isolation, dedicated Ebola treatment units) and safe-burial protocols (avoiding traditional washing of bodies, which exposes funeral attendees to the virus) are the two highest-impact non-pharmaceutical interventions. Survivor follow-up matters as well: Zaire ebolavirus persists in immune-privileged sites (eye, central nervous system, testis) for months in some survivors and can cause flare cases and onward transmission long after the original outbreak is declared over.

Treatment notes

Two monoclonal antibody therapies are licensed for Zaire ebolavirus disease: Inmazeb (atoltivimab/maftivimab/odesivimab, a three-antibody cocktail) and Ebanga (ansuvimab, a single antibody). Both target the viral glycoprotein and showed substantial mortality reductions versus historical controls in the 2018-2020 DRC PALM trial. Supportive care remains foundational — aggressive fluid resuscitation, electrolyte correction, oxygen, treatment of secondary infections — and accounts for much of the historical mortality improvement in well-resourced treatment units even before specific therapeutics existed.

Where Zaire ebolavirus circulates

Documented in the following countries. Click through for country-specific context, active outbreak status, and historical cases.

Related strains

• SUDV Endemic to Uganda and South Sudan with case-fatality of roughly 40 to 70 percent. No licensed vaccine or therapeutic exists for Sudan virus, though candidates are in trials.
• BDBV The lowest-mortality ebolavirus species, with case-fatality of 25 to 40 percent. Cause of the 2026 DRC/Uganda PHEIC outbreak and discovered in western Uganda in 2007.
• TAFV The rarest human-pathogenic ebolavirus, with only one documented human case — a Swiss ethologist who survived after a chimpanzee necropsy in 1994.

Synthesized from World Health Organization Ebola fact sheets, U.S. Centers for Disease Control and Prevention Ebola disease pages, the European Centre for Disease Prevention and Control surveillance atlas, and primary epidemiological literature. Not a substitute for individual medical advice. If you have been exposed to a confirmed or suspected case and develop symptoms, contact a healthcare professional immediately.

Continue exploring: complete guide to hantavirus · live outbreak dashboard · global map